NO20032069L - SN-38 lipidkomplekser og fremgangsmåte for anvendelse derav - Google Patents

SN-38 lipidkomplekser og fremgangsmåte for anvendelse derav

Info

Publication number
NO20032069L
NO20032069L NO20032069A NO20032069A NO20032069L NO 20032069 L NO20032069 L NO 20032069L NO 20032069 A NO20032069 A NO 20032069A NO 20032069 A NO20032069 A NO 20032069A NO 20032069 L NO20032069 L NO 20032069L
Authority
NO
Norway
Prior art keywords
complexes
compositions
lipid complexes
present
cardiolipin
Prior art date
Application number
NO20032069A
Other languages
English (en)
Norwegian (no)
Other versions
NO20032069D0 (no
Inventor
Imran Ahmad
Jia-Ai Allen Zhang
Aquilur Rahman
Original Assignee
Neopharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neopharm Inc filed Critical Neopharm Inc
Publication of NO20032069D0 publication Critical patent/NO20032069D0/no
Publication of NO20032069L publication Critical patent/NO20032069L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20032069A 2000-11-09 2003-05-08 SN-38 lipidkomplekser og fremgangsmåte for anvendelse derav NO20032069L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24730600P 2000-11-09 2000-11-09
PCT/US2001/043325 WO2002058622A2 (en) 2000-11-09 2001-11-09 Sn-38 lipid complexes and methods of use

Publications (2)

Publication Number Publication Date
NO20032069D0 NO20032069D0 (no) 2003-05-08
NO20032069L true NO20032069L (no) 2003-07-02

Family

ID=22934406

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20032069A NO20032069L (no) 2000-11-09 2003-05-08 SN-38 lipidkomplekser og fremgangsmåte for anvendelse derav

Country Status (22)

Country Link
US (1) US7390502B2 (ru)
EP (1) EP1355634B8 (ru)
JP (1) JP4524071B2 (ru)
KR (1) KR100869824B1 (ru)
CN (1) CN1531424A (ru)
AT (1) ATE413164T1 (ru)
AU (1) AU2002246510B2 (ru)
BG (1) BG107862A (ru)
BR (1) BR0115260A (ru)
CA (1) CA2427467C (ru)
CZ (1) CZ20031515A3 (ru)
DE (1) DE60136490D1 (ru)
EA (1) EA006741B1 (ru)
HU (1) HUP0302352A3 (ru)
IL (1) IL155696A0 (ru)
MX (1) MXPA03004095A (ru)
NO (1) NO20032069L (ru)
NZ (1) NZ525552A (ru)
PL (1) PL363618A1 (ru)
SK (1) SK7092003A3 (ru)
WO (1) WO2002058622A2 (ru)
ZA (1) ZA200303432B (ru)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7262173B2 (en) 1997-03-21 2007-08-28 Georgetown University Chemosensitizing with liposomes containing oligonucleotides
WO2003030864A1 (en) * 2001-05-29 2003-04-17 Neopharm, Inc. Liposomal formulation of irinotecan
WO2003018018A2 (en) * 2001-08-24 2003-03-06 Neopharm, Inc. Vinorelbine compositions and methods of use
EP1448237A1 (en) * 2001-11-09 2004-08-25 Neopharm, Inc. Selective treatment of il-13 expressing tumors
US7138512B2 (en) * 2002-04-10 2006-11-21 Georgetown University Gene SHINC-2 and diagnostic and therapeutic uses thereof
EP1513853A2 (en) * 2002-05-24 2005-03-16 Neopharm, Inc. Cardiolipin compositions, methods of preparation and use
EA200401565A1 (ru) * 2002-05-24 2005-04-28 Неофарм, Инк. Способ получения кардиолипина или аналога кардиолипина (варианты), способ получения липосомы и композиция кардиолипина для лечения заболеваний (варианты)
AU2003240934A1 (en) * 2002-05-29 2003-12-19 Neopharm, Inc. Method for determining oligonucleotide concentration
WO2004035032A2 (en) * 2002-08-20 2004-04-29 Neopharm, Inc. Pharmaceutical formulations of camptothecine derivatives
WO2004017944A1 (en) * 2002-08-23 2004-03-04 Neopharm, Inc. Liposomal gemcitabine compositions for better drug delivery
US20050277611A1 (en) * 2002-10-16 2005-12-15 Neopharm, Inc. Cationic cardiolipin analoges and its use thereof
BRPI0407096A (pt) * 2003-02-03 2006-01-24 Neopharm Inc Taxano encapsulado em lipossomo estável, estéril e filtrável e outros fármacos antineoplásicos
EA200501285A1 (ru) * 2003-02-11 2006-02-24 Неофарм, Инк. Способ получения липосомальных препаратов
WO2004087758A2 (en) * 2003-03-26 2004-10-14 Neopharm, Inc. Il 13 receptor alpha 2 antibody and methods of use
WO2005000266A2 (en) * 2003-05-22 2005-01-06 Neopharm, Inc. Liposomal formulations comprising a combination of two or more active agents
US20060078560A1 (en) * 2003-06-23 2006-04-13 Neopharm, Inc. Method of inducing apoptosis and inhibiting cardiolipin synthesis
EP1759699B1 (en) * 2004-06-18 2016-01-20 Kabushiki Kaisha Yakult Honsha Liposome preparation containing slightly water-soluble camptothecin
EA200700626A1 (ru) * 2004-09-15 2007-10-26 Васоджен Айеленд Лимитед Лечение множественного склероза
CA2699184A1 (en) * 2006-09-22 2008-03-27 Labopharm Inc. Compositions and methods for ph targeted drug delivery
US20100008998A1 (en) * 2006-09-26 2010-01-14 Samyang Corporation Submicron nanoparticle of poorly water soluble camptothecin derivatives and process for preparation thereof
WO2008127358A2 (en) * 2006-10-10 2008-10-23 Jina Pharmaceuticals, Inc. Aqueous systems for the preparation of lipid-based pharmaceutical compounds; compositions, methods, and uses thereof
EP2088865B1 (en) 2006-11-06 2015-10-21 Jina Pharmaceuticals Inc. Guggulphospholipid methods and compositions
US8067432B2 (en) * 2008-03-31 2011-11-29 University Of Kentucky Research Foundation Liposomal, ring-opened camptothecins with prolonged, site-specific delivery of active drug to solid tumors
WO2010045199A2 (en) * 2008-10-13 2010-04-22 University Of South Florida Method of modulating ship activity
JP2012526049A (ja) * 2009-05-04 2012-10-25 インテザイン テクノロジーズ， インコーポレイテッド 腫瘍治療のためのｓｎ−３８を含有するポリマーミセル
US20110207764A1 (en) * 2010-02-23 2011-08-25 Valery Alakhov Cyclopolysaccharide compositions
US20110207760A1 (en) * 2010-02-23 2011-08-25 Valery Alakhov Sn-38 compositions
WO2011119995A2 (en) 2010-03-26 2011-09-29 Cerulean Pharma Inc. Formulations and methods of use
CN104856931B (zh) * 2014-02-24 2019-06-18 石药集团中奇制药技术（石家庄）有限公司 一种两性霉素b纳米复合物及其制备方法
MX2016010998A (es) 2014-02-27 2017-03-31 Lycera Corp Terapia celular adoptiva que usa un agonista de receptor huérfano gamma relacionado con receptor de ácido retinoico y métodos terapéuticos relacionados.
EP3140291A4 (en) 2014-05-05 2018-01-10 Lycera Corporation Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease
EP3292119A4 (en) 2015-05-05 2018-10-03 Lycera Corporation DIHYDRO-2H-BENZO[b][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE
US10611740B2 (en) 2015-06-11 2020-04-07 Lycera Corporation Aryl dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
CN110302171A (zh) * 2019-07-12 2019-10-08 山东大学 一种瘤内注射用sn-38-plga缓释微球及其制备方法和应用
US11286344B2 (en) 2020-01-10 2022-03-29 Tyndall Formulation Services, LLC Polymer excipients for drug delivery applications
WO2021142020A1 (en) * 2020-01-10 2021-07-15 Tyndall Formulation Services, LLC Formulations of sn-38 with poly(amino acid) block polymers
CA3231432A1 (en) * 2021-10-15 2023-04-20 Tianyi Ke Composition containing antitumor drug, and preparation method therefor and use thereof

Family Cites Families (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS180644B2 (en) 1973-09-29 1978-01-31 Takeda Chemical Industries Ltd Process for preparing nonapeptides
US3993754A (en) 1974-10-09 1976-11-23 The United States Of America As Represented By The United States Energy Research And Development Administration Liposome-encapsulated actinomycin for cancer chemotherapy
JPS5186117A (en) 1975-01-27 1976-07-28 Tanabe Seiyaku Co Johoseibiryushiseizainoseiho
US4115544A (en) 1976-08-18 1978-09-19 Alza Corporation Ocular system made of bioerodible esters having linear ether
GB1575343A (en) 1977-05-10 1980-09-17 Ici Ltd Method for preparing liposome compositions containing biologically active compounds
CH621479A5 (ru) 1977-08-05 1981-02-13 Battelle Memorial Institute
CH624011A5 (ru) 1977-08-05 1981-07-15 Battelle Memorial Institute
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
CA1173360A (en) 1979-06-22 1984-08-28 Jurg Schrank Pharmaceutical preparations
HU184141B (en) 1979-12-27 1984-07-30 Human Oltoanyagtermelo Adjuvant particles compositions containing said particles and biologically active substances adsorbed thereon and a process for the preparation thereof
US4348384A (en) 1980-10-17 1982-09-07 Dainippon Pharmaceutical Co., Ltd. Pharmaceutical composition for oral administration containing coagulation factor VIII or IX
US4419348A (en) 1981-04-27 1983-12-06 Georgetown University Anthracycline glycoside compositions, their use and preparation
US4473692A (en) 1981-09-04 1984-09-25 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives and process for preparing same
US4522803A (en) 1983-02-04 1985-06-11 The Liposome Company, Inc. Stable plurilamellar vesicles, their preparation and use
US4515736A (en) 1983-05-12 1985-05-07 The Regents Of The University Of California Method for encapsulating materials into liposomes
US4610868A (en) 1984-03-20 1986-09-09 The Liposome Company, Inc. Lipid matrix carriers for use in drug delivery systems
US4721612A (en) 1984-04-12 1988-01-26 The Liposome Company, Inc. Steroidal liposomes
AU587600B2 (en) * 1985-01-11 1989-08-24 Regents Of The University Of California, The Method for preserving liposomes
US4857319A (en) 1985-01-11 1989-08-15 The Regents Of The University Of California Method for preserving liposomes
US5023087A (en) 1986-02-10 1991-06-11 Liposome Technology, Inc. Efficient method for preparation of prolonged release liposome-based drug delivery system
US5187167A (en) 1986-03-27 1993-02-16 Imperial Chemical Industries Plc Pharmaceutical compositions comprising quinazolin-4-one derivatives
US4812312A (en) 1987-03-03 1989-03-14 Board Of Regents Of The University Of Texas System Liposome-incorporated nystatin
US5616334A (en) 1987-03-05 1997-04-01 The Liposome Company, Inc. Low toxicity drug-lipid systems
US5276019A (en) 1987-03-25 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5264423A (en) 1987-03-25 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US4981968A (en) 1987-03-31 1991-01-01 Research Triangle Institute Synthesis of camptothecin and analogs thereof
JP2780755B2 (ja) * 1987-05-22 1998-07-30 ザ リポソーム カンパニー，インコーポレイテッド プロスタグランジン‐脂質製剤
GB8727737D0 (en) 1987-11-26 1987-12-31 Ici Plc Antitumour agents
MX9203504A (es) 1988-04-20 1992-07-01 Liposome Co Inc Complejo agente: lipido activo de alta proporcion.
US4952408A (en) 1988-05-23 1990-08-28 Georgetown University Liposome-encapsulated vinca alkaloids and their use in combatting tumors
US5077057A (en) 1989-04-05 1991-12-31 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
US5003097A (en) 1989-10-02 1991-03-26 The United States Of America As Represented By The Department Of Health And Human Services Method for the sulfurization of phosphorous groups in compounds
US5620689A (en) * 1989-10-20 1997-04-15 Sequus Pharmaceuuticals, Inc. Liposomes for treatment of B-cell and T-cell disorders
US5552154A (en) 1989-11-06 1996-09-03 The Stehlin Foundation For Cancer Research Method for treating cancer with water-insoluble s-camptothecin of the closed lactone ring form and derivatives thereof
US5389377A (en) 1989-12-22 1995-02-14 Molecular Bioquest, Inc. Solid care therapeutic compositions and methods for making same
US5665710A (en) 1990-04-30 1997-09-09 Georgetown University Method of making liposomal oligodeoxynucleotide compositions
US5422344A (en) 1990-05-08 1995-06-06 The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services Method of treating retroviral infections in mammals
US5543389A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization Covalent polar lipid-peptide conjugates for use in salves
US5162532A (en) 1990-12-20 1992-11-10 North Carolina State University Intermediates and method of making camptothecin and camptothecin analogs
US5247089A (en) 1990-12-20 1993-09-21 North Carolina State University Method of making intermediates useful for the manufacture of camptothecin and camptothecin analogs
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5603872A (en) * 1991-02-14 1997-02-18 Baxter International Inc. Method of binding recognizing substances to liposomes
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
PT706373E (pt) 1992-03-23 2000-11-30 Univ Georgetown Taxol encapsulado num liposoma e um metodo
US5391745A (en) 1992-07-23 1995-02-21 Sloan-Kettering Institute For Cancer Research Methods of preparation of camptothecin analogs
WO1994005259A1 (en) 1992-09-02 1994-03-17 Georgetown University Method of encapsulating anthracycline glycosides in liposomes
US5552156A (en) * 1992-10-23 1996-09-03 Ohio State University Liposomal and micellular stabilization of camptothecin drugs
US5916596A (en) 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US5352789A (en) 1993-02-25 1994-10-04 The Stehlin Foundation For Cancer Research Methods for purifying camptothecin compounds
US5527913A (en) 1993-02-25 1996-06-18 The Stehlin Foundation For Cancer Research Methods for purifying camptothecin compounds
US5776486A (en) 1993-05-28 1998-07-07 Aphios Corporation Methods and apparatus for making liposomes containing hydrophobic drugs
US5405963A (en) 1993-06-10 1995-04-11 Smithkline Beecham Corporation Process for asymmetric total synthesis of camptothecin analogues
US5475108A (en) 1993-08-31 1995-12-12 North Carolina State University Camptothecin intermediates and method of making camptothecin and comptothecin analogs
WO1995008986A1 (en) * 1993-09-27 1995-04-06 Smithkline Beecham Corporation Camptothecin formulations
TW406020B (en) 1993-09-29 2000-09-21 Bristol Myers Squibb Co Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent
JP2828391B2 (ja) * 1993-10-29 1998-11-25 東燃株式会社 オリゴ糖を表面に有するリポソーム
US5447936A (en) 1993-12-22 1995-09-05 Bionumerik Pharmaceuticals, Inc. Lactone stable formulation of 10-hydroxy 7-ethyl camptothecin and methods for uses thereof
US5786344A (en) 1994-07-05 1998-07-28 Arch Development Corporation Camptothecin drug combinations and methods with reduced side effects
US5626862A (en) 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
DE69535665T2 (de) 1994-08-19 2009-04-02 La Region Wallonne Konjugate enthaltend ein antitumorales mittel und deren verwendung
US5776743A (en) 1994-09-06 1998-07-07 La Jolla Cancer Research Foundation Method of sensitizing tumor cells with adenovirus E1A
US5496830A (en) 1994-09-14 1996-03-05 Johns Hopkins University Inhibition of hemoflagellates by camptothecin compounds
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US5919816A (en) 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
US5736156A (en) 1995-03-22 1998-04-07 The Ohio State University Liposomal anf micellular stabilization of camptothecin drugs
US5834012A (en) * 1995-05-03 1998-11-10 Roman Perez-Soler Lipid complexed topoisomerase I inhibitors
US5726181A (en) 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
US5972955A (en) 1995-06-06 1999-10-26 Dr. Reddy's Research Foundation Water soluble C-ring analogues of 20(S)-camptothecin
SG50747A1 (en) 1995-08-02 1998-07-20 Tanabe Seiyaku Co Comptothecin derivatives
AU7732996A (en) 1995-11-22 1997-06-11 Research Triangle Institute Camptothecin compounds with combined topoisomerase i inhibition and dna alkylation properties
GB9601779D0 (en) 1996-01-30 1996-04-03 Pharmacia Spa 9, 10 Disubstituted camptothecin derivatives
US6096336A (en) * 1996-01-30 2000-08-01 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
US6056973A (en) * 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US5759767A (en) 1996-10-11 1998-06-02 Joseph R. Lakowicz Two-photon and multi-photon measurement of analytes in animal and human tissues and fluids
US5837282A (en) 1996-10-30 1998-11-17 University Of British Columbia Ionophore-mediated liposome loading
US5948750A (en) 1996-10-30 1999-09-07 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
TW464652B (en) 1996-10-30 2001-11-21 Tanabe Seiyaku Co S type 2-substituted hydroxy-2-indolidinylbutyric ester compounds and process for preparation thereof
US6495579B1 (en) * 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
US5827533A (en) 1997-02-06 1998-10-27 Duke University Liposomes containing active agents aggregated with lipid surfactants
US7262173B2 (en) * 1997-03-21 2007-08-28 Georgetown University Chemosensitizing with liposomes containing oligonucleotides
US20030229040A1 (en) * 1997-03-21 2003-12-11 Georgetown University Cationic liposomal delivery system and therapeutic use thereof
US6126965A (en) 1997-03-21 2000-10-03 Georgetown University School Of Medicine Liposomes containing oligonucleotides
US6559129B1 (en) * 1997-03-21 2003-05-06 Georgetown University Cationic liposomal delivery system and therapeutic use thereof
NZ503293A (en) * 1997-09-16 2002-09-27 Nexstar Pharmaceuticals Inc Liposomal camptothecin formulations also comprising at least one phospholipid
US6090407A (en) 1997-09-23 2000-07-18 Research Development Foundation Small particle liposome aerosols for delivery of anti-cancer drugs
US6183958B1 (en) 1998-05-06 2001-02-06 Variagenics, Inc. Probes for variance detection
WO1999066072A2 (en) 1998-06-16 1999-12-23 Nova Molecular, Inc. Methods for treating a neurological disease by determining bche genotype
US6461637B1 (en) * 2000-09-01 2002-10-08 Neopharm, Inc. Method of administering liposomal encapsulated taxane
US6146659A (en) 1998-07-01 2000-11-14 Neopharm, Inc. Method of administering liposomal encapsulated taxane
US6664062B1 (en) * 1998-07-20 2003-12-16 Nuvelo, Inc. Thymidylate synthase gene sequence variances having utility in determining the treatment of disease
ATE238039T1 (de) * 1998-09-16 2003-05-15 Alza Corp In liposomen eingeschlossene topoisomerase inhibitoren
US6610492B1 (en) * 1998-10-01 2003-08-26 Variagenics, Inc. Base-modified nucleotides and cleavage of polynucleotides incorporating them
US6500650B1 (en) * 1998-10-01 2002-12-31 Variagenics, Inc. Method for identifying polymorphisms
US6458945B1 (en) * 1998-10-01 2002-10-01 Variagenics, Inc. Method for analyzing polynucleotides
US6777188B2 (en) * 1998-10-01 2004-08-17 Variagenics, Inc. Genotyping by mass spectrometric analysis of allelic fragments
WO2000020634A1 (en) * 1998-10-01 2000-04-13 Nova Molecular, Inc. Methods for treating or identifying a subject at risk for a neurological disease by determining the presence of a variant gpiiia and/or variant gpiib allele
US6395481B1 (en) * 1999-02-16 2002-05-28 Arch Development Corp. Methods for detection of promoter polymorphism in a UGT gene promoter
EP1216309A2 (en) * 1999-03-01 2002-06-26 Variagenics, Inc. Methods for targeting rna molecules
US6291676B1 (en) * 1999-03-03 2001-09-18 University Of Kentucky Research Foundation Water-soluble derivatives of camptothecin/homocamptothecin
US6573049B1 (en) * 1999-07-26 2003-06-03 Nuvelo, Inc. Genotyping of the paraoxonase 1 gene for prognosing, diagnosing, and treating a disease
US6475736B1 (en) * 2000-05-23 2002-11-05 Variagenics, Inc. Methods for genetic analysis of DNA using biased amplification of polymorphic sites
EA200300473A1 (ru) * 2000-10-16 2003-08-28 Неофарм, Инк. Терапевтическая композиция на основе митоксантрона (варианты) и липидный препарат, способ его получения и способ лечения заболевания млекопитающего с его использованием
WO2002059337A1 (en) * 2001-01-26 2002-08-01 Georgetown University School Of Medicine Anti-apoptopic gene scc-s2 and diagnostic and therapeutic uses thereof
AU2002303261A1 (en) * 2001-04-06 2002-10-21 Georgetown University Gene brcc2 and diagnostic and therapeutic uses thereof
AU2002305151A1 (en) * 2001-04-06 2002-10-21 Georgetown University Gene scc-112 and diagnostic and therapeutic uses thereof
WO2002081642A2 (en) * 2001-04-06 2002-10-17 Georgetown University Gene brcc-3 and diagnostic and therapeutic uses thereof
WO2003030864A1 (en) * 2001-05-29 2003-04-17 Neopharm, Inc. Liposomal formulation of irinotecan
EP1448237A1 (en) * 2001-11-09 2004-08-25 Neopharm, Inc. Selective treatment of il-13 expressing tumors
US7138512B2 (en) * 2002-04-10 2006-11-21 Georgetown University Gene SHINC-2 and diagnostic and therapeutic uses thereof
US7244565B2 (en) * 2002-04-10 2007-07-17 Georgetown University Gene shinc-3 and diagnostic and therapeutic uses thereof
WO2003099213A2 (en) * 2002-05-20 2003-12-04 Neopharm, Inc. Method for reducing platelet count
US20030228317A1 (en) * 2002-05-22 2003-12-11 Prafulla Gokhale Gene BRCC-1 and diagnostic and therapeutic uses thereof
EP1513853A2 (en) * 2002-05-24 2005-03-16 Neopharm, Inc. Cardiolipin compositions, methods of preparation and use
EA200401565A1 (ru) * 2002-05-24 2005-04-28 Неофарм, Инк. Способ получения кардиолипина или аналога кардиолипина (варианты), способ получения липосомы и композиция кардиолипина для лечения заболеваний (варианты)
AU2003240934A1 (en) * 2002-05-29 2003-12-19 Neopharm, Inc. Method for determining oligonucleotide concentration
WO2004035032A2 (en) * 2002-08-20 2004-04-29 Neopharm, Inc. Pharmaceutical formulations of camptothecine derivatives
WO2004017944A1 (en) * 2002-08-23 2004-03-04 Neopharm, Inc. Liposomal gemcitabine compositions for better drug delivery
US20050277611A1 (en) * 2002-10-16 2005-12-15 Neopharm, Inc. Cationic cardiolipin analoges and its use thereof

Also Published As

Publication number Publication date
HUP0302352A3 (en) 2007-03-28
KR100869824B1 (ko) 2008-11-21
EP1355634A2 (en) 2003-10-29
BR0115260A (pt) 2005-08-16
ZA200303432B (en) 2004-08-05
CN1531424A (zh) 2004-09-22
EA200300550A1 (ru) 2004-06-24
EP1355634B1 (en) 2008-11-05
CA2427467A1 (en) 2002-08-01
EA006741B1 (ru) 2006-04-28
KR20030072352A (ko) 2003-09-13
IL155696A0 (en) 2003-11-23
US20030215492A1 (en) 2003-11-20
DE60136490D1 (de) 2008-12-18
JP2004529086A (ja) 2004-09-24
CA2427467C (en) 2010-01-12
EP1355634A4 (en) 2005-07-06
MXPA03004095A (es) 2004-09-10
US7390502B2 (en) 2008-06-24
NO20032069D0 (no) 2003-05-08
EP1355634B8 (en) 2009-03-04
ATE413164T1 (de) 2008-11-15
CZ20031515A3 (cs) 2003-09-17
AU2002246510B2 (en) 2007-09-20
SK7092003A3 (en) 2004-06-08
WO2002058622A2 (en) 2002-08-01
HUP0302352A2 (hu) 2003-11-28
AU2002246510A2 (en) 2002-08-06
BG107862A (bg) 2004-06-30
WO2002058622A3 (en) 2003-08-28
JP4524071B2 (ja) 2010-08-11
PL363618A1 (en) 2004-11-29
NZ525552A (en) 2005-04-29

Similar Documents

Publication Publication Date Title
NO20032069L (no) SN-38 lipidkomplekser og fremgangsmåte for anvendelse derav
EP1432714A4 (en) CHEMICAL COMPOUNDS
NO20032759L (no) 2-fenylbenzimidazoler og imidazo-[4,5]-pyridiner som Cds1/Chk2-inhibitorerog adjuvanter for kjemoterapi eller strålingsterapi ved behandlingav cancer
CY1106357T1 (el) Παραγωγα αδαμαντανιου για τη θepαπεια φλεγμονωδων, ανοσολογικων και καρδιαγγειακων ασθενειων
EP1435946B8 (en) Linked biaryl compounds
ATE515514T1 (de) Verwendungen von säuger-cytokin il-23 ; verwandte reagenzien
CY1106816T1 (el) 1,5-δισυποκαταστημενες ενωσεις 3,4-διυδρο-1h-πυριμιδο [4,5-d] πυριμιδιν-2-ονης και η χρησιμοποιηση αυτων δια τη θεραπευτικη αγωγη ασθενειων εις τις οποιες μεσολαβει η csbp/p38 κιναση
ATE238307T1 (de) Substituierte porphyrinen
EA200301091A1 (ru) Противоопухолевые комбинации, такие как рапамицин вместе с гемцитабином или фторурацилом
ES2191152T3 (es) Terapia combinada para el tratamiento de psicosis.
PL1615952T3 (pl) Sposoby leczenia chorób zapalnych z zastosowaniem środków specyficznie wiążących ludzką angiopoetynę-2
CY1110259T1 (el) Ανοσορυθμιστης
CR7182A (es) Benzoilsufanamidas y sulfonilbenzamidinas que se usan como agentes antitumorales
UA88638C2 (ru) Бета-карболины, полезные для лечения воспалительного заболевания
DE60021381D1 (de) Chinonverbindungen zur behandlung von krankheiten
EA200500244A1 (ru) Тетрапропиламмония тетратиомолибдат и родственные соединения для антиангиогенной терапии
ATE249835T1 (de) Immunoregulator
ATE188873T1 (de) Tris-platin-komplexe
AU2002350623A1 (en) Targeted thrombosis by tissue factor polypeptides
MXPA03007413A (es) Composicion y metodo para tratar enfermedades inflamatorias.
DE60130659D1 (de) Therapeutische verbindungen und verfahren
AU2013204147B2 (en) Treatment of TNFalpha related disorders
UA35854A (ru) Способ лечения скрыто протекающего силикотуберкулеза
ATE455121T1 (de) Herstellungsverfahren von derivate von bisphosphonaten
UA51058A (ru) Способ лечения поражений суставов

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application